Category Archives: Stem Cell Medicine

Missouri S&T researchers create organ tissue with bioactive glass, stem cells and 3D printer – The Rolla Daily News

Researchers also working on 3D-printed bone models that showcase the types of research that complement the University of Missouri Systems NextGen Precision Health Initiative.

An interdisciplinary team of Missouri University of Science and Technology researchers is creating organ tissue samples using bioactive glass, stem cells and a 3D printer, the university announced Thursday. The project could advance pharmaceutical testing and lead to a better understanding of how diseases affect human cells.

The researchers grow stem cells and add them to hydrogels made of alginate, gelatin or similar substances. Then, in a step unique to Missouri S&T, the researchers add bioactive glass to supply needed calcium ions to the hydrogel/cell mixture and load the mixture as bioink into a 3D printer. They test the samples after bioprinting to determine the stem cell function, the materials tensile strength, degradation and the best glass type to add.

Different cells prefer different gels, so we work to find which gel combination suits our research, says Dr. Krishna Kolan, a postdoctoral researcher at S&T. The challenge is that dissolved glass adds calcium, but it changes the pH, and cells need neutral pH to survive. We figured out which glass and how much to add to maintain neutral pH.

Kolan says researchers are several years away from making a functioning organ, such as a liver or kidney, and the challenge is the vascular system and multiple types of cells in those organs. Missouri S&T researchers are working on ways to develop vascular systems within the bioprinted tissue. Kolan says they can imbed a channel into engineered tissue during printing, then line the channel with endothelial cells, which are the primary cells in blood vessels.

He is working on the experiments with two undergraduate students: August Bindbeutel (mechanical engineering) and Lesa Steen (materials science and engineering).

Endothelial cells form networks in environments they like, such as glass-infused hydrogel, Kolan says. As the network grows, it vascularizes the tissue.

As researchers work toward someday repairing or replacing organs with engineered organs, they are creating tissue models that can be used for pharmaceutical testing, Kolan says. Companies can scale down the composition of a drug to be appropriate for a tissue sample, he says.

Missouri S&T researchers are also currently working on 3D-printed bone models. Biology graduate student Bradley Bromet is comparing diseased cells with healthy stem cells to see in 3D how a disease diabetes, for instance affects cells.

Kolan is working on the project with Dr. Ming Leu, the Bailey Professor in Missouri S&Ts mechanical and aerospace engineering department; Dr. Richard Brow, interim deputy provost in the materials science and engineering department; Dr. Delbert Day, Curators' Professor Emeritus of ceramic engineering, and Dr. Julie Semon, assistant professor of biology and director of S&Ts Laboratory of Regenerative Medicine.

The research project showcases the types of research that complement the University of Missouri Systems NextGen Precision Health Initiative. NextGen is expected to accelerate medical breakthroughs and improve lives by harnessing the research being done at the systems four universities and training a new generation of health scientists and practitioners.

Here is the original post:
Missouri S&T researchers create organ tissue with bioactive glass, stem cells and 3D printer - The Rolla Daily News

Regenerative Medicine Market trends, leaders, segment analysis and forecast to 2030 described in a new market report – WhaTech Technology and Markets…

Technological innovations in the area of stem cell therapy and tissue engineering has led to rapid growth of the regenerative medicine market size.

Regenerative medicine is a comparatively new area of science that involves the restoration of damaged cells, tissues or organs by applying cell therapy, tissue engineering, immunotherapy or gene therapy techniques. On contrary to the present clinical therapeutics that act on slowing the disease progression or relieve symptoms, regenerative medication has a promising therapeutic approach of restoring the function and structure of damaged organs and tissues.

The global regenerative medicine market is expected to witness significant growth during the forecast period,due to the increase in the prevalence of chronic diseases, orthopaedic injuries, genetic disorders, growing aging population, increasing government funding along with the private funding in the research & development of regenerative medicines with the advancement in nanotechnology based drug delivery system, and moderate healthcare reforms. Currently, major breakthrough in the area is the development of tissue engineered trachea, transplantation of retinal pigment differentiated by stem cell based therapy to treat age-related macular degeneration.

However, recently research labs have started to focus on regenerating solid organs such as heart, kidney, lungs and other organs to curb the problems associated with organ transplantation.

The rise in number of regulatory approvals of regenerative medications is expected to further drive the regenerative medicine market during the forecast period. Moreover, there has been strategic partnership between many companies that has encouraged increased involvement of these companies in the global market.

Improvised drug delivery systems for regenerative medicines is also expected to contribute to the growth of the global market.

Download sample copy of this report at:www.psmarketresearch.com/market-ort-sample

The key factors which drive the growth of the global market include increase in the demand of orthopaedic surgeries, government healthcare reforms in certain countries such as the U.S. and Canada, aging population, rise in chronic diseases, increasing prevalence of bone and joint diseases, and innovations in nanotechnology that aids in drug delivery mechanism.

Globally, North America is the largest market for regenerative medicine followed by Europe. The largest regenerative medicine market size of North America is attributed to the high rate of incidence of cardiac disorders, autoimmune diseases, and increasing prevalence of cancer patients among the American population.

Additionally, the involvement of government organization for funding in the area of R&D of regenerative medicines, technological advancement and other policies are driving the growth of the North American market.

MARKET SEGMENTATION

By Type

By Therapy

Pre-AccessInquiry at:www.psmarketresearch.com/send-enine-market

By Application

This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow this link:
Regenerative Medicine Market trends, leaders, segment analysis and forecast to 2030 described in a new market report - WhaTech Technology and Markets...

5 Aesthetic Clinics To Know In The Klang Valley & Their Signature Treatments – Malaysia Tatler

Flawless skin and more beauty fixes at these top aesthetic clinics around town

Sign up for our weekly newsletter to get all our top stories delivered

Were on Facebook and Instagram. Follow us for the latest news, events and happenings

Located at The Shoppes at Four Seasons Place, La Jung is Kuala Lumpurs newest anti-aging and aesthetic clinic, offering anti-aging solutions from Switzerland in partnership with leading Swiss medical clinics.

Helmed by Cardiff-trained aesthetic medical practitioner Dr Nicholas Lim, La Jung spans 5,275sf and comprises five plush treatment rooms, two VIP waiting rooms, a VIP lounge, a VVIP waiting and treatment room, and even a discrete alternative entrance leading directly to the carpark.

Signature treatments: The Sylfirm treatment helps to suppress a common type of skin pigmentation among Asians known as melasma, according Dr. Nicholas. This sophisticated procedure uses technology developed in Silicon Valley, and is typically used to treat melasma in addition to laser treatment in more stubborn cases.

PicoPlus is another specialty of La Jung. It refers to the use of a second-generation pico and nano-second laser to tackle blotchy pigmentation with minimal damage to the surrounding tissue.

Call 03-2856 7616 for more information.

Photos: The Glitz Of La Jung Malaysia's Grand Opening

Beverley Wilshire Medical Centre offers medical aesthetic treatments, anti-ageing medicine, cosmetic surgery, dental aesthetics and hair restoration at its main branch in Jalan Tun Razak. The clinic is known for its non-surgical treatments including V-shape face and nose reshaping.

Signature treatments: A trusted name in cosmetic tourism packages, Beverley Wilshire Medical Centres cosmetic vacation is an all-in-one deal, pairing treatments with an overnight stay at one of its luxury suites or a partner hotel nearby, plus meals, post-op follow-ups and even airport transfers.

Call 03-2118 2888 for more information.

The art of aging gracefully is yours to explore at the Bangsar-based M.A.C Clinic, which specialises in non-invasive or minimally invasive treatments that require little to no downtime.

Offering treatments in body slimming, breast enhancements and laser treatments to preventive age management that targets health risk factors in ones lifestyle, M.A.C clinic is helmed by Dr Hew Yin Keat, a founding member of the Malaysian Society of Aesthetic Medicine.

Signature treatments: Dubbed The Liquid Face Lift, this procedure uses injectable fillers to minimise sagging skin and fine lines without the downtime of plastic surgery, according to Dr Hew. The Picosure Laser treatment is another highly sought-after treatment to improve the appearance of acne, scars and other pigmentation. Other signatures include regenerative medicine, stem cell treatments, the Infini Scar Treatment, and CoolSculpting by Zeltiq.

Call 03-2283 1212 for more information.

Related: MAC Clinic Unveils First PicoSure Laser Treatment in Malaysia In An Exclusive Party At Marinis On 57

Helmed by medical director Prof Dr Edmond Ng (also assistant professor and consultant at the Faculty of Medicine & Health Sciences at UCSI University), Xeoul Clinic boasts a team of full-time consultant aesthetic doctors with more than 10 years of experience.

A beauty clinic under the umbrella of the Xeoul Global brand, Xeoul Clinic specialises in face and skin, weight loss and hair treatments.

Signature treatments: Q-switch NdYag Laser treatment, Fractional CO2 Laser treatment, chemical peels and Regenera Activa for hair enhancement. Weight loss treatments include the BTL Vanquish Me and BTL Vanquish Flex procedures.

Call 03-5613 0023 for more information.

Dr Park Wonjin of Wonjin Beauty Medical Group: Achieving A More Beautiful You

Did you know that Da Vinci Clinic is regularly patronised by one of the cast members of the Netflix series Ghost Bride and feature film The Garden of Evening Mists?

This upscale clinic can be found at The Boulevard Office, Mid Valley City as well as in Cheras and Kepong. It offers face, skin, body and hair treatments in addition to holistic wellness programmes. From dimples creation, lip enhancements and breast augmentation to Botulinum Toxin injections to reduce oversized calves, Da Vinci Clinic operates on the philosophy of helping patients improve on the "minute elements" to unleash the true potential of beauty.

Signature treatments: The Da Vinci Double Eyelid Creation Treatment and Thermage, a non-invasive cosmetic procedure that eases the appearance of stretch marks, wrinkles, fine lines and sagging or uneven skin.

Call 03-2283 2888 for more information.

More here:
5 Aesthetic Clinics To Know In The Klang Valley & Their Signature Treatments - Malaysia Tatler

Tech Ventures kicks off series dedicated to supporting female inventors and entrepreneurs at Johns Hopkins – The Hub at Johns Hopkins

BySaralyn Cruickshank

Of all the things that helped Barb Slusher on her path to becoming a leader in the field of drug discovery and an inventor with more than 70 patents to her name, the relationships she built with her peers, and particularly her female peers, were the most influential. By building relationships, she said, she was able to secure funding for her pharmaceutical ventures while still working in the industry, and the bonds she built with other women in pharma help ensure her voice is heard, even in a room full of men.

"If I look at the people who have invested money in the companies we've started, I've usually started a relationship with that person before. I've consulted for them, I've been to conferences with them, I've been on panels or boards with them. They get to know me and trust me, and that ultimately leads to them investing in my companies. It takes time," said Slusher, a Johns Hopkins alum who now directs the Johns Hopkins Drug Discovery Program. "I'm also used to being the only woman in the room, but when I'm with other women, we team up to make sure that each other's opinions are heard."

Slusher was one of three panelists to share insights about being a woman in innovation during an invitational breakfast event held Wednesday at FastForward U near the Johns Hopkins Homewood campus. Alongside stem cell researcher Sharon Gerecht and biomedical engineer Natalia Trayanova, Slusher spoke to 40 of the university's most prominent women in technology and entrepreneurshipfaculty, staff, and studentswho had gathered to network and share their experiences.

Image credit: Will Kirk / Johns Hopkins University

"I hope that 2020 is a year we acknowledge the lengths that female entrepreneurs go," said Christy Wyskiel, senior advisor to the president of Johns Hopkins University for innovation and entrepreneurship and executive director of Johns Hopkins Technology Ventures. "For Johns Hopkins women, in particular, I am committed to helping them find the sponsorship they need in the form of mentors, investors, board members, and believers in a more equal way."

Hosted by Johns Hopkins Technology Ventures, the event kicked off the AccelHERator event series, a collection of workshops and talks focused on supporting female inventors and entrepreneurs at Johns Hopkins. The series, funded by a grant from the Small Business Association, aims to address the barriers to success experienced by women in tech and business, and to support them and their work. Attendees of the launch event were largely those known by or already working with Tech Ventures, but organizers say they hope more members of the Johns Hopkins community will participate in the program by nominating women entrepreneurs and innovators to join the movement through an online form.

Image credit: Will Kirk / Johns Hopkins University

"The work of bringing research to the market is really difficult, in that it requires both cutting-edge science and a keen understanding of customers and how markets function," said Liz Burger, senior director of strategic initiatives at Tech Ventures. "We need all the talent we can get; we cannot afford to have women participate less. So today is a celebration of the vast potential of women at Johns Hopkins, and the rest of the events in the series are about equipping women with the tools to take action and move ideas forward."

Casey Overby Taylor, an assistant professor of medicine and an expert in biomedical informatics, attended the event to learn more about Tech Ventures and to network with other female entrepreneurs.

"I wanted to explore what it would take to build my own private, commercial business, so this is a good way to get exposed to this topic," Overby Taylor said.

Another attendee, Bailey Surtees, graduated from Johns Hopkins in 2017 and now heads a startup that operates out of FastForward U, the student-focused accelerator and makerspace where the breakfast event was held. She said she was interested in the event because she was looking for an opportunity to connect with other entrepreneurial women.

"The female professors that I had as a student at Hopkins made a big impact on my experience," Surtees said. "Seeing how they balanced being a professional woman at the top of their field and other goals I share with them, like being part of a family, was really cool and helped prepare me for what it's like to be a woman in business."

The next AccelHERator event will be a workshop about creating successful value propositions that help capture potential startup customers and clients. It takes place from 11 a.m. to 1 p.m. on Wednesday, April 1, at FastForward 1812 on the East Baltimore campus. Those interested in attending can register online. Additional events will be held in May and June.

See more here:
Tech Ventures kicks off series dedicated to supporting female inventors and entrepreneurs at Johns Hopkins - The Hub at Johns Hopkins

BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update – GlobeNewswire

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and full year ended December 31, 2019, and provide a corporate update, at 8:00 a.m., Eastern Time, on Tuesday, February 18, 2020.

BrainStorms President & CEO, Chaim Lebovits, will present the full year 2019 corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, and Preetam Shah, PhD, Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.comand questions should be submitted by 5:00 p.m., Eastern Time, Monday, February 17 2020.

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. Brainstorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. Brainstorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: 862-397-8160pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Here is the original post:
BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update - GlobeNewswire

CD229 CAR T-cell therapy treated tumours had lasting response mice – Drug Target Review

Researchers have created a CAR T-cell therapy which targets the CD229 molecule expressed on all multiple myeloma cells and killed human tumour cells in mice.

Collaborative work at the University of Utah (U of U) has resulted in a CAR T-cell therapy that targets the CD229 molecule expressed on all multiple myeloma cells. The researchers showed that both in cell lines and mice with human multiple myeloma tumours, there was a long-lasting response to the treatment.

The paper published in Nature Communications, builds on previous research where the scientists had shown CD229 was expressed on all multiple myeloma cells, including the myeloma stem cells, which can reform the tumour after therapy.

We were dismayed that although some of our patients respond quite well to currently available immunotherapies, they relapsed as early as one year after treatment, said Dr Djordje Atanackovic, physician-scientist at Huntsman Cancer Institute (HCI) and an Associate Professor of Internal Medicine in the Division of Hematology and Hematologic Malignancies at the U of U. We thought if we could target every last cancer cell in a patients body, including the cancer stem cell, this could make the critical difference and yield more durable, deeper responses to treatment.

According to the researchers, it took several years to engineer the current agent to target CD229. The resultant agent consists of a fully human anti-CD229 antibody, with a hook which can produce CAR T cells targeting CD229.

In multiple myeloma patient stem cells, and mouse models, the scientists showed their CD229 CAR T cells could kill mature multiple myeloma cells. In these tests, the researchers said that the tumours treated with CD229 CAR T appeared to have long-lasting responses.

The team are planning to further analyse if this approach can be safely used in humans and hope to open clinical trials to understand the potential of CD229 as a novel therapy for multiple myeloma.

Read the original here:
CD229 CAR T-cell therapy treated tumours had lasting response mice - Drug Target Review

BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update – BioSpace

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and full year ended December 31, 2019, and provide a corporate update, at 8:00 a.m., Eastern Time, on Tuesday, February 18, 2020.

BrainStorms President & CEO, Chaim Lebovits, will present the full year 2019 corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, and Preetam Shah, PhD, Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com and questions should be submitted by 5:00 p.m., Eastern Time, Monday, February 17 2020.

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwn

NurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn Cellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. Brainstorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. Brainstorm received U.S. FDA clearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) in December 2018 and has been enrolling clinical trial participants since March 2019. For more information, visit the company's website.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: 862-397-8160pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Here is the original post:
BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update - BioSpace

Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma – Cancer Network

Early results from a phase I/II trial, published inThe New England Journal of Medicine, found that a majority of patients with either relapsed or refractory non-Hodgkins lymphoma (NHL) or chronic lymphocytic leukemia (CLL) treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.1

Additionally, there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline; however, the maximum tolerated dose was not reached.

We are encouraged by the results of the clinical trial, which will launch further clinical studies to investigate allogeneic cord blood-derived CAR NK cells as a potential treatment option for patients in need, corresponding author Katy Rezvani, MD, PhD, professor of stem cell transplantation and cellular therapy at The University of Texas MD Anderson Cancer Center, said in a press release.2

In this study cohort of 11 patients with relapsed or refractory CD-19 positive cancers, participants were given a single dose of cord blood-derived CD19 CAR NK cells at 1 of 3 dose levels. Five of the patients had CLL and the remaining 6 had NHL. All of the patients were treated with a minimum of 3 and a maximum of 11 lines of prior therapy. The first 9 participants treated were given CD19 CAR NK cells that were partially matched according to the individuals HLA type, but protocol allowed the last 2 patients to be treated with no HLA matching.

Eight (73%) of the participants had a response, and of those, 7 (4 with NHL and 3 with CLL) had a complete remission, while 1 had remission of the Richters transformation component, but had persistent CLL. The responses were rapid and observed within 30 days after infusion at all dose levels. The infused CAR NK cells expanded and persisted at low levels for at least 12 months.

According to the researchers, a proportion of patients treated with anti-CD19 CAR T cells have a subsequent relapse, with a 1-year progression-free survival of approximately 30% observed among patients with CLL and 45% seen among those with NHL.

In view of these outcomes, our study allowed for remission consolidation therapy with an immunomodulatory agent, anticancer drug, or hematopoietic stem-cell transplantation at the discretion of the treating physician, the authors wrote. However, the use of post-remission therapy in this study limits our assessment of the durability of response after CAR NK therapy.

Notably, researchers did observe high-grade transient myelotoxicity in the cohort, of which they attributed to the lymphodepleting chemotherapy. However, they were unable to assess whether the CAR NK cells contributed to the myelotoxicity.

Side effects experienced by the patients were primarily related to the conditioning chemotherapy given before cell infusion and were resolved within 1 to 2 weeks, according to Rezvani. Additionally, no patient required admission to an intensive care unit for management of treatment side effects.

Due to the nature of the therapy, weve actually been able to administer it in an outpatient setting, Rezvani said. We look forward to building upon these results in larger multi-center trials as we work with Takeda to make this therapy available more broadly.

References:

1. Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.The New England Journal of Medicine. doi:10.1056/NEJMoa1910607.

2. CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma [news release]. Houston, Texas. Published February 5, 2020. app.bronto.com/public/viewmessage/html/6781/hemm7h92mwb6849npf2js0r4mhnrl/0bd003eb00000000000000000000000df096. Accessed February 6, 2020.

See original here:
Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, Lymphoma - Cancer Network

Physical forces at the interface with biology and chemistry – PLoS Blogs

Cell behaviour, tissue formation/regulation, physiology and disease are all influenced by cellular mechanics and physical forces. The field of mechanobiology has for a long time striven to fully understand how these forces affect biological and cellular processes, as well as developing new analytical techniques. At the same time, the properties of advanced smart materials, such as self-healing, self-reporting and responsive polymers, have been determined by a complex interplay between the thermodynamics, kinetics and mechanics of dynamic bonding strategies. These are tightly connected to the field of mechanochemistry, whichaims to elucidate and harness molecular level design principles and translate these to the bulk material level as emergent properties. At this interface between disciplines lies an emerging and exciting research area that has been strongly facilitated by the collaboration of physicists, chemists, engineers, materials scientists, and biologists.

We had the pleasure of speaking to Kerstin Blank and Matthew Harrington, who have been working on how mechanical forces influence biological systems, molecules and responsive biomaterials, about their views of the field and the recent Multiscale Mechanochemistry and Mechanobiology conference of which PLOS ONE was one of the proud sponsors.

How did you first become interested in this topic?

Kerstin: When I started in this field in 2000, I was mostly impressed by the technical possibilities. I was working with Hermann Gaub, one of the leaders in single-molecule force spectroscopy. I found it fascinating that we could stretch a single biological molecule and observe its response. I did ask myself sometimes if this was just something that physicists like to play with or if one could solve biomedically relevant questions with this approach. Now, almost 20 years later, it has become very evident that a large number of biological systems are regulated by mechanical forces in many different ways.

Matt: My educational background was primarily in biology and biochemistry, but I became fascinated with the capacity of certain biological materials to exhibit self-healing responses in the absence of living cells. I reasoned that this must arise from specific chemical and physical design principles in the material building blocks themselves, and I became obsessed with figuring out how this works. This led me to the self-healing materials community, which was largely populated with chemists and materials engineers, but not so many biologists. When I began to see that many of the same principles at play in synthetic self-healing materials were present in nature, and that in some cases nature was going well beyond the state of the art in synthetic self-healing materials, I realized the enormous potential at the interface of mechanobiology and mechanochemistry. I havent looked back since.

Which areas are you most excited about?

Kerstin: I find it very intriguing how cells utilize mechanical information from their environment and then feed it into intracellular biochemical signalling cascades. Understanding these mechanosensing and mechanotransduction processes requires knowledge of the cellular players and their interactions. But to develop the complete picture, we also need to investigate how cells interact with their extracellular environment. This also involves understanding the microscopic and macroscopic mechanical properties of the extracellular environment. I am highly excited about the development of molecular force sensors that convert mechanical force into a fluorescent signal. This allows for the localized detection of cell traction forces and, in the future, will also enable us to visualize force propagation inside materials that mimic the natural extracellular matrix.

Matt: I am currently most excited about understanding how and why nature uses different transient interactions to control the fabrication and viscoelastic mechanical responses of biopolymeric materials and the potential this has for the development of sustainable advanced polymers of the future. Recent discoveries in the field clearly show that in contrast to traditional polymers, living organisms commonly use specific supramolecular interactions based on dynamic bonds (e.g. hydrogen bonding, metal coordination or pi-cation interactions) to guide the self-assembly and mechanical properties of protein-based materials. The thermodynamic and kinetic properties of these labile bonds enable a certain dynamicity and responsiveness in these building blocks that provides potential inspiration for environmentally friendly materials processing and active/tuneable material properties. These concepts are already being adapted in a number of exciting bio-inspired polymers.

What progress has the field made in the last years?

Kerstin: It is now well-established that cells are able to sense and respond to the elastic and viscoelastic properties of the material they grow in. We have also learned a lot about how the mechanical signal is converted into biochemical signalling on the intracellular side. This is a direct result of many new technological developments, including the molecular force sensors described above. It is further a result of the increasing development of extracellular matrix mimics with well-defined and tuneable mechanical properties and microstructures.

Matt: Due to recent technological advances it is becoming possible to link specific aspects of mechanical material responses directly to structural features at multiple length scales. The better we understand these structure-property relationships, the better we can optimize the material response. This provides an intimate feedback loop that has enabled major breakthroughs in the fields of active matter, including self-healing and self-reporting polymers.

What is the real-world impact?

Kerstin: It is widely accepted that mechanical information plays a key role in stem cell differentiation. It has further been shown that mutated cells, e.g. in cancer or cardiovascular diseases, have different mechanical properties and show alterations in processing mechanical information. Understanding the origin of these changes and being able to interfere with them will have direct impact in disease diagnostics and treatment. Engineering materials with molecularly controlled structures and mechanical properties will further enable the community to direct stem cell differentiation in a more defined manner for applications in tissue engineering and regenerative medicine.

Matt: Aside from biomedical impacts, the insights gained from understanding the structure-function relationships defining the mechanical response of molecules are also extremely relevant for the development and sustainable fabrication of next generation advanced polymers. Given the global threat of petroleum-based plastics processing and disposal, this is an extremely important aspect of the research in this field.

What are the challenges and future developments of the field?

Kerstin: At this moment, we usually try to relate the macroscopic material properties (measured in the lab) with the microscopic environment that cells sense. In my view, we are missing a key piece of information. We need to understand how the macroscopic properties of a material emerge from its molecular composition, topography and hierarchical structure. In combination, all these parameters determine the mechanical properties of a material and, more importantly, what the cells see. In fact, this is not only key for the development of new extracellular matrix mimics. The same questions need to be answered for understanding how nature assembles a wide range of structural and functional materials with outstanding properties, such as spider silk, cellulose composites and nacre. Here, I see a great potential for future collaboration between disciplines.

Matt: There are enormous challenges on the bio-inspiration side of the field involved with transferring design principles extracted from biological materials into synthetic systems. Biology is inherently complex, so there is a common tendency to distil the extracted concept to a single functional group or concept, while often there are collective effects that are lost by this more reductionist approach. On the biological side, a key challenge is ascertaining which are the relevant design principles. On the bio-inspired side, there are challenges in finding appropriate synthetic analogues to mimic the chemical and structural complexity of the natural system. Overcoming this barrier requires cross-disciplinary communication and feedback and is an extremely exciting and active area in our field.

Why and when did you decide to organize a conference on this topic?

Kerstin & Matt: While both working at the Max Planck Institute of Colloids and Interfaces, we quickly realized that the cell biophysics, biomaterials, mechanochemistry and soft matter communities are all interested in very similar questions while using similar methods and theoretical models; however, we had the impression that they hardly interact with each other. We thought of ways to change this and organizing a conference was clearly one way to do it. The first conference with the topic Multiscale Mechanochemistry and Mechanobiology: from molecular mechanisms to smart materials took place in Berlin in 2017. When bringing this idea forward in our respective communities, we immediately realized that we hit a nerve. Now that the conference has taken place for the second time in Montreal in 2019, we really got the feeling that we are starting to create a community around this topic. There will be another follow up conference from August 23-25, 2021 in Berlin (@mcb2021Berlin).

What are the most interesting and representative papers published in PLOS ONE in this field?

Kerstin: The paper Monodisperse measurement of the biotin-streptavidin interaction strength in a well-defined pulling geometry, published by Sedlak et al., is a highly interesting contribution to the field of single-molecule force spectroscopy, which was also presented at the conference. This work highlights the methodological developments in single-molecule force spectroscopy since its very early days. The authors from the Gaub labhave re-measured the well-known streptavidin-biotin interaction, now with a very high level of control over the molecular setup. It clearly shows how far the field has come and also that protein engineering, bioconjugation chemistry, instrumentation development and data analysis all need to go hand in hand to obtain clear and unambiguous experimental results. Clearly, considering a defined molecular setup is not only crucial for this kind of measurement but also for the development of biomimetic materials with controlled mechanical properties.

Sedlak SM, Bauer MS, Kluger C, Schendel LC, Milles LF, Pippig DA, et al. (2017) Monodisperse measurement of the biotin-streptavidin interaction strength in a well-defined pulling geometry. PLoS ONE 12(12): e0188722,https://doi.org/10.1371/journal.pone.0188722

Matt: Accurately detecting and measuring the mechanical forces at play inside living cells is one of the key challenges in the field of mechanobiology, given the small size and dynamic nature of the intracellular environment. However, this information is extremely important for understanding the role of mechanics in regulating cellular functions such as growth, differentiation and proliferation, as well as disease states. In the Nuclei deformation reveals pressure distributions in 3D cell clusters paper from the Ehrlicher group, the authors address this challenge by using fluorescently labelled proteins in the cell nucleus coupled with confocal microscopy to measure compressive pressures within cells and cell clusters. Using this methodology, they explored the effect of cell number and shape of multicellular clusters on the internal compressive pressure within cells, providing potentially important insights for cellular signalling and function. These studies have potential applications in both in vitro and in vivo models, and provide a relatively simple methodology for acquiring intracellular mechanical data.

Khavari A, Ehrlicher AJ (2019) Nuclei deformation reveals pressure distributions in 3D cell clusters. PLoS ONE 14(9): e0221753,https://doi.org/10.1371/journal.pone.0221753

Other PLOS ONE representative papers:

Kerstin Blank studied Biotechnology at the University of Applied Sciences in Jena and obtained her PhDin Biophysics under the supervision of Prof Hermann Gaub at Ludwig-Maximilians Universitt in Munich. After two postdocs at the Universit de Strasbourg and the Katholieke Universiteit Leuven, she became an Assistant Professor at Radboud University in Nijmegen in 2009. In 2014, she moved to the Max Planck Institute of Colloids and Interfaces where she holds the position of a Max Planck Research Group Leader. Her research interests combine biochemistry and single molecule biophysics with the goal of developing molecular force sensors for biological and materials science applications.

Matthew J. Harrington is Canada Research Chair in Green Chemistry and assistant professor in Chemistry at McGill University since 2017. He received his PhD in the lab of J. Herbert Waite from the University of California, Santa Barbara. Afterwards, he was a Humboldt postdoctoral fellow and then research group leader at the Max Planck Institute of Colloids and Interfaces in the Department of Biomaterials. His research interests are focused on understanding biochemical structure-function relationships and fabrication processes of biopolymeric materials and translating extracted design principles for production of sustainable, advanced materials.

Link:
Physical forces at the interface with biology and chemistry - PLoS Blogs

Scientists create ‘Chemical gardens’ that can be used as bone substitute materials – University of Birmingham

Calcium phosphate tubular structures

A new way of making bone-replacement materials that allows for cells to grow around and inside them has been developed by researchers at the University of Birmingham.

The team adopted a novel approach called chemobrionics, in which chemical components are controllably driven to react together in specific ways, enabling the self-assembly of intricate bio-inspired structures.

Scientists first observed these life-like chemical gardens several hundred years ago, but recent renewed interest in the field of chemobrionics has seen researchers using these techniques to design new materials at the micro- and nanoscale.

The Birmingham researchers set out to explore whether chemobrionics could also be harnessed for biotechnological applications.

Lead author Erik Hughes, of the School of Chemical Engineering at the University of Birmingham, explains We set out to investigate if chemobrionics could be used to form architectures that are chemically and structurally similar to human bone. Once a method of generating such structures is established, the natural next step forward is to evaluate if chemobrionic materials can provide ideal frameworks for bone regeneration.

The team used a calcium-loaded gel layered under a phosphate solution, and succeeded in growing long microscale hollow tubes of hydroxyapatite material that is similar in composition to natural bone. Hydroxyapatite is commonly used as a bone substitute material, but it is typically manufactured as a powder or as a hard block, which then needs to be shaped with further processing.

The individual structures grown by the Birmingham team are approximately as thick as a strand of human hair. These tubes possess distinctive features, including porous surfaces that promote interactions with cells. Published in RSC Biomaterials Science, the study demonstrates the similarity of the tubes to many of the structures found in bone tissue, such as osteons long cylindrical channels in bone that house blood vessels.

We can find lots of examples of chemobrionic principles at work in nature, explains Erik. For example, on the ocean floor, we see hot mineral-rich fluids emitted from hydrothermal vents that react with the cool seawater to form chimney-like structures. We are exploiting these same mechanisms to make these new structures for applications in regenerative medicine.

The team have tested the ability of the tubes to support cell attachment, viability and growth in the laboratory using stem cells. They were able to show extensive spreading of the cells upon and extending within the tubes after only 48 hours, indicating favourable cell-material interactions.

Using chemobrionics to produce materials that are biocompatible is a relatively new approach, but we are really excited by its potential, says co-first author Miruna Chipara, who is also based in the School of Chemical Engineering at the University of Birmingham. In particular, the way these structures promote cellular integration means they could be widely useful for bone regeneration.

The next steps for the researchers include carrying out further tests to demonstrate the properties of the tubular materials and how they may be modified to improve tissue regeneration. The researchers are hopeful that their work will lead to the development of a new class of chemobrionic bone substitute materials.

Originally posted here:
Scientists create 'Chemical gardens' that can be used as bone substitute materials - University of Birmingham